GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigenic vaccines and immunotherapies, reported its financial results for the year ended December 31, 2025, and provided an update on key operational achievements. The company's primary focus is advancing GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine candidate targeting mpox and smallpox, toward late-stage clinical development. GeoVax plans to initiate a pivotal Phase 3 immuno-bridging study in the second half of 2026, following regulatory alignment with the European Medicines Agency (EMA) and completion of manufacturing milestones.
David Dodd, Chairman and CEO of GeoVax, stated that GEO-MVA represents a critically important opportunity to eliminate the current global supply constraint in orthopoxvirus vaccines while supporting broader public health preparedness and biosecurity objectives. The company believes GEO-MVA is uniquely positioned at the intersection of recurring global mpox outbreaks, depleted government stockpiles, and policy-driven demand for diversified and domestic vaccine supply. During 2025, GeoVax received formal Scientific Advice from the EMA supporting a streamlined development pathway, completed cGMP manufacturing and fill-finish of clinical-grade GEO-MVA, and is now preparing for the Phase 3 trial.
Beyond GEO-MVA, GeoVax continues to advance other pipeline programs. GEO-CM04S1, a next-generation COVID-19 vaccine, is progressing through multiple Phase 2 trials targeting immunocompromised populations, with data readouts expected in 2026. Interim DSMB findings in a chronic lymphocytic leukemia (CLL) study indicated superior immune responses compared to an mRNA comparator. In oncology, Gedeptin, a gene-directed enzyme prodrug therapy, completed a Phase 1/2 trial in advanced head and neck cancer, and the company plans to initiate a Phase 2 trial for first-line treatment in 2027, potentially in combination with immune checkpoint inhibitors.
Financially, GeoVax reported a net loss of $21.5 million for 2025, compared to $25.0 million in 2024. Revenue from government contracts was $2.5 million, down from $4.0 million in 2024, primarily due to the termination of the BARDA/RRPV Project NextGen contract in April 2025. Research and development expenses decreased to $18.1 million from $23.7 million, largely due to discontinued costs associated with the BARDA contract and lower costs for GEO-CM04S1 and Gedeptin programs. General and administrative expenses increased to $6.0 million from $5.4 million, driven by higher personnel costs and investor relations consulting. Cash and cash equivalents stood at $3.1 million as of December 31, 2025, compared to $5.5 million at the end of 2024.
The company's ability to execute its clinical and regulatory milestones will be critical for advancing GEO-MVA toward potential approval and addressing global orthopoxvirus vaccine needs. GeoVax continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com.
